Functional characterization of a novel FGFR1OP‐RET rearrangement in hematopoietic malignancies

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Molecular Oncology

• Publication date

  2014-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.molonc.2013.11.004PMID 24315414PMCID PMC5528547
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Functional characterization of a novel FGFR1OP‐RET rearrangement in hematopoietic malignancies

  2014cited by this paper
• Transformation of a Chronic Myeloproliferative Neoplasm to Acute Myelogenous Leukemia: Does Anything Work?

  2012cited by this paper
• Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

  2012cited by this paper
• KIF5B-RET fusions in lung adenocarcinoma

  2012cited by this paper
• Essential role for Stat 5 a / b in myeloproliferative neoplasms induced by BCR-ABL 1 and JAK 2 V 617 F in mice

  2012cited by this paper
• Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia

  2012cited by this paper
• Mutations in epigenetic regulators in myelodysplastic syndromes

  2012cited by this paper
• The structural basis for control of eukaryotic protein kinases.

  2012cited by this paper
• Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture.

  2012cited by this paper
• Myeloproliferative neoplasia: a review of clinical criteria and treatment.

  2012cited by this paper
• Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management

  2012cited by this paper
• The classification of MDS: from FAB to WHO and beyond.

  2012cited by this paper
• RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation

  2012cited by this paper
• RET, ROS1 and ALK fusions in lung cancer

  2012cited by this paper
• Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.

  2011cited by this paper
• Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.

  2011cited by this paper
• Mouse models of myeloproliferative neoplasms: JAK of all grades

  2011cited by this paper
• Recurrent DNMT3A Mutations in Patients with Myelodysplastic Syndromes

  2011cited by this paper
• Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors

  2011cited by this paper
• JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia.

  2010cited by this paper
• ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia

  2010cited by this paper
• Insights into the stem cells of chronic myeloid leukemia

  2010cited by this paper
• Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML

  2009cited by this paper
• The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

  2009cited by this paper
• Acquired mutations in TET2 are common in myelodysplastic syndromes

  2009cited by this paper
• Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.

  2009cited by this paper
• Myeloproliferative disorder FOP-FGFR1 fusion kinase recruits phosphoinositide-3 kinase and phospholipase Cγ at the centrosome

  2008cited by this paper
• Identification and transcript analysis of a novel wallaby (Macropus eugenii) basal-like breast cancer cell line

  2008cited by this paper
• Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies

  2008cited by this paper
• Treatment of chronic myeloid leukemia in blast crisis

  2008cited by this paper
• Ras/ERK1/2-mediated STAT3 Ser727 Phosphorylation by Familial Medullary Thyroid Carcinoma-associated RET Mutants Induces Full Activation of STAT3 and Is Required for c-fos Promoter Activation, Cell Mitogenicity, and Transformation*

  2007cited by this paper
• Hematopoietic cytokine receptor signaling

  2007cited by this paper
• Structure of the N-terminal domain of the FOP (FGFR1OP) protein and implications for its dimerization and centrosomal localization.

  2006cited by this paper
• Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

  2006cited by this paper
• Drug Insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer

  2006cited by this paper
• A complex of two centrosomal proteins, CAP350 and FOP, cooperates with EB1 in microtubule anchoring.

  2005cited by this paper
• A gain-of-function mutation of JAK2 in myeloproliferative disorders.

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

  2005cited by this paper
• RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.

  2005cited by this paper
• Impairment of p53 acetylation, stability and function by an oncogenic transcription factor

  2004cited by this paper
• JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis

  2004cited by this paper
• PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors.

  2002cited by this paper
• The GDNF/RET signaling pathway and human diseases.

  2001cited by this paper
• New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia.

  2001cited by this paper
• Diagnostic criteria and classification of mastocytosis: a consensus proposal.

  2001cited by this paper
• Cell signaling by receptor tyrosine kinases.

  2000cited by this paper
• Control of myeloid differentiation and survival by Stats

  2000cited by this paper
• Cell signaling by receptor tyrosine kinases.

  2000cited by this paper
• The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1.

  1999cited by this paper
• Use of green fluorescent protein variants to monitor gene transfer and expression in mammalian cells

  1996cited by this paper
• Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B

  1995cited by this paper
• Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma.

  1994cited by this paper
• Conditions controlling the proliferation of haemopoietic stem cells in vitro

  1977cited by this paper

• Accurate RET Fusion Detection in Solid Tumors Using RNA Sequencing Coverage Imbalance Analysis

  2025cites this paper
• Fusion Genes Landscape of Lung Cancer Patients From Inner Mongolia, China

  2024cites this paper
• Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer, and RET-mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial

  2023cites this paper
• Predictive molecular pathology in metastatic thyroid cancer: the role of RET fusions

  2022cites this paper
• Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer

  2021cites this paper
• Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases

  2021cites this paper
• Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.

  2021cites this paper
• State-of-the-Art Strategies for Targeting RET-Dependent Cancers.

  2020cites this paper
• RET Gene Fusions in Malignancies of the Thyroid and Other Tissues

  2020cites this paper
• Targeting the RNA-Binding Protein QKI in Myeloid Cells Ameliorates Macrophage-Induced Renal Interstitial Fibrosis

  2020cites this paper
• Ensemble disease gene prediction by clinical sample-based networks

  2020cites this paper
• Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology

  2020cites this paper
• Identifying disease-associated genes based on artificial intelligence

  2019cites this paper
• Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer.

  2019cites this paper
• ANKRD26-RET - A novel gene fusion involving RET in papillary thyroid carcinoma.

  2019cites this paper
• REToma: a cancer subtype with a shared driver oncogene.

  2019cites this paper
• Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes

  2018cites this paper
• Hypoxia‐induced tRNA‐derived fragments, novel regulatory factor for doxorubicin resistance in triple‐negative breast cancer

  2018cites this paper
• The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.

  2017cites this paper
• Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays: findings and recommendations

  2017influential citation
• The ba/f3 transformation assay: characterization of a novel csf2rb-activating variant, and the discovery of acquired mutations in ba/f3 cells

  2017cites this paper
• Acute leukaemia and myelodysplastic syndromes with chromosomal rearrangement involving 11q23 locus, but not MLL gene

  2016cites this paper
• A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma

  2016cites this paper
• The RET Receptor Family

  2015cites this paper
• Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase

  2015cites this paper
• RET and Thyroid Carcinomas

  2015cites this paper
• Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

  2015cites this paper
• Wrecked regulation of intrinsically disordered proteins in diseases: pathogenicity of deregulated regulators

  2014cites this paper
• Uncovering Proximity of Chromosome Territories using Classical Algebraic Statistics

  2014cites this paper
• Functional characterization of a novel FGFR1OP‐RET rearrangement in hematopoietic malignancies

  2014cites this paper